Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Arcadia Biosciences (RKDA) Divestments (2022 - 2023)

Arcadia Biosciences filings provide 2 years of Divestments readings, the most recent being $284000.0 for Q2 2023.

On a quarterly basis, Divestments changed N/A to $284000.0 in Q2 2023 year-over-year; TTM through Mar 2024 was $284000.0, a 66.74% decrease, with the full-year FY2023 number at $569000.0, changed 0.0% from a year prior.
Divestments hit $284000.0 in Q2 2023 for Arcadia Biosciences, roughly flat from $285000.0 in the prior quarter.
In the past five years, Divestments ranged from a high of $285000.0 in Q3 2022 to a low of $284000.0 in Q4 2022.